Survivin and XIAP: two valuable biomarkers in medullary thyroid carcinoma

BACKGROUND: Medullary thyroid carcinoma (MTC) accounts for ∼5% of all thyroid malignancies. To date, surgery is the first-line therapy with curative intention. However, for advanced MTC, conventional chemotherapeutic agents do not provide convincing results. Therefore, the identification of biomarke...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Cancer
Egile Nagusiak: Werner, Thomas A, Tamkan-Ölcek, Yasemin, Dizdar, Levent, Riemer, Jasmin C, Wolf, Achim, Cupisti, Kenko, Verde, Pablo E, Knoefel, Wolfram T, Krieg, Andreas
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2016
Gaiak:
Translational Therapeutics
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4815780/
https://ncbi.nlm.nih.gov/pubmed/26882066
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.5
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak